- Home
- CARM
as 10-07-2025 3:30pm EST
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 12.1M | IPO Year: | N/A |
| Target Price: | $0.90 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.14 - $1.27 | Next Earning Date: | 11-06-2025 |
| Revenue: | $10,767,000 | Revenue Growth: | -48.01% |
| Revenue Growth (this year): | -48.04% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Carisma Therapeutics Inc. (CARM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klichinsky Michael | CARM | Chief Scientific Officer | Oct 3 '25 | Sell | $0.26 | 119,347 | $31,077.96 | 0 | |
| Klichinsky Michael | CARM | Chief Scientific Officer | Oct 2 '25 | Sell | $0.25 | 200,000 | $50,860.00 | 0 | |
| Klichinsky Michael | CARM | Chief Scientific Officer | Oct 1 '25 | Sell | $0.26 | 165,000 | $42,405.00 | 0 |
Latest Carisma Therapeutics Inc. News
CARM Breaking Stock News: Dive into CARM Ticker-Specific Updates for Smart Investing
TipRanks
3 months ago
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
MT Newswires
3 months ago
Carisma Therapeutics to Merge With OrthoCellix in All-Stock Transaction
GlobeNewswire
3 months ago
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
Simply Wall St.
6 months ago
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations
MT Newswires
6 months ago
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce
PR Newswire
6 months ago
Carisma Therapeutics Provides Corporate Updates
PR Newswire
8 months ago
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
PR Newswire
8 months ago
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compare CARM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CARM Carisma Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.